Evidence map›Paper›PMID 42544316›Full record

ArticleCureus2026

Functional Recovery Following Post-vaccination Neurological Syndrome With Demyelinating Findings on Magnetic Resonance Imaging (MRI): A Case Report.

Hisham Hobbi, Mohammad Al-Jumaily, Hisham Al Hakim

Abstract readCase Reports
In one paragraph

Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Hisham HobbiMedicine, Damascus University, Damascus, SYR.
Mohammad Al-JumailyNeurosurgery, American Spine Center, Dubai, ARE.
Hisham Al HakimNeurology, American Spine Center, Dubai, ARE.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Rare neurological syndromes have been reported following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination, although a causal relationship remains uncertain. We report the case of a 62-year-old woman who developed progressive neurological impairment temporally associated with BNT162b2 (Pfizer-BioNTech) COVID-19 vaccination, resulting in wheelchair dependence. Brain magnetic resonance imaging (MRI) demonstrated multiple periventricular T2-weighted/fluid-attenuated inversion recovery (T2/FLAIR) hyperintense lesions, including lesions oriented perpendicular to the lateral ventricles, consistent with demyelinating features. A multimodal therapeutic approach was implemented, including gut-directed therapy, intravenous gold-induced cytokine (GOLDIC®) therapy, hyperbaric oxygen therapy (HBOT), intranasal exosome therapy, and structured neurorehabilitation. Over the course of treatment, the patient showed substantial clinical improvement, including recovery of ambulation and functional neurological status. While this case highlights the potential for significant neurological involvement following SARS-CoV-2 vaccination and the possibility of recovery with a multimodal therapeutic approach, the contribution of the individual therapies cannot be determined. Further research is needed to better understand the underlying mechanisms and to evaluate emerging therapeutic strategies, including GOLDIC, in this setting.

Indexed as

bnt162b2case reportdemyelinationexosomegoldichbotneurorehabilitationpfizer-biontechvaccine-associated neurological syndrome

Identifiers

PMID42544316
PMCPMC13429209

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.